Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Cancer save search
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
ITOS | $10.58 2.42% 2.36% 940K
|
Health Technology
|
| O: -1.0%
H: 2.26%
C: -1.29%
eos-984 association cancer cell research preclinical for meeting
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
CRBU | $3.87 -1.02% -1.03% 1.7M
|
Health Technology
|
| O: 1.63%
H: 0.54%
C: -0.67%
cb-012 association cancer cell research preclinical meeting car-t
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
Published: 2023-11-06 (Crawled : 14:00) - globenewswire.com
ABUS | News | $2.725 -0.18% -0.18% 930K
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
company cancer cell immunotherapy
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
Published: 2023-11-02 (Crawled : 14:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
t-cell cancer blood therapy
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Published: 2023-10-31 (Crawled : 20:00) - globenewswire.com
CLLS | $2.47 0.4% 12K
|
Health Technology
|
| O: 179.38%
H: 10.33%
C: -2.58%
pre-clinical breast cancer immunotherapy meeting
EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Published: 2023-10-18 (Crawled : 15:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
cancer cell preclinical immunotherapy meeting therapeutics potential platform
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Published: 2023-09-27 (Crawled : 20:00) - globenewswire.com
CLLS | $2.47 0.4% 12K
|
Health Technology
|
| O: -1.25%
H: 2.22%
C: 0.0%
pre-clinical breast cancer immunotherapy meeting
Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Published: 2023-09-27 (Crawled : 14:00) - biospace.com/
ACET | $1.95 -3.7% -3.85% 730K
|
Health Technology
|
| O: 0.7%
H: 4.86%
C: 0.0%
cancer cell immunotherapy meeting platform
CAR T-cell Therapy: Genetically Modifying the Immune System to Attack Blood Cancer and Clinical Applications in Nursing Practice
Published: 2023-08-23 (Crawled : 13:30) - nanthealth.com
NHIQ | $0.341 16.76% 110
|
Information
|
| O: -2.5%
H: 0.0%
C: 0.0%
t-cell cancer blood system
City of Hope researchers develop a CAR T cell therapy for advanced ovarian cancer
Published: 2023-08-10 (Crawled : 15:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
hope cancer cell city therapy
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
Published: 2023-07-11 (Crawled : 13:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.7%
H: 0.12%
C: -2.36%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
antibody t-cell cancer treat therapeutics
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
Published: 2023-06-29 (Crawled : 11:00) - globenewswire.com
GNLX | $4.13 7.0% 6.54% 130K
|
|
| O: -0.03%
H: 3.07%
C: -1.54%
patent corporation cancer cell treatment
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
Published: 2023-06-05 (Crawled : 20:00) - prnewswire.com
PGEN | $1.33 0.76% 0.75% 1M
|
Health Technology
|
| O: -0.75%
H: 2.26%
C: -2.26%
prgn-3005 day positive cancer
IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
Published: 2023-05-17 (Crawled : 12:00) - globenewswire.com
INAB | $1.0 -4.76% -5.0% 280K
|
|
| O: 0.37%
H: 5.33%
C: 3.73%
cancer promise show
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology
Published: 2023-05-09 (Crawled : 14:00) - prnewswire.com
GDTC | $2.125 1.68% 1.65% 3.8K
|
|
| O: -11.56%
H: 23.08%
C: -8.97%
cancer collaboration therapeutics
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
Published: 2023-04-18 (Crawled : 16:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
association cancer cell research meeting therapeutics results platform
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2023-04-17 (Crawled : 07:00) - biospace.com/
CLLS | $2.47 0.4% 12K
|
Health Technology
|
| O: 0.0%
H: 1.47%
C: 0.0%
talen breast association cancer research preclinical meeting negative
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
Published: 2023-04-16 (Crawled : 20:20) - globenewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: 4.71%
H: 5.81%
C: 2.93%
afm13 association cancer cell research meeting study
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
Published: 2023-03-14 (Crawled : 22:00) - globenewswire.com
CLLS | $2.47 0.4% 12K
|
Health Technology
|
| O: -3.54%
H: 2.09%
C: -4.19%
talen research meeting breast association presentation cancer negative
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Published: 2023-01-25 (Crawled : 14:00) - allogene.com
ALLO | $3.48 0.58% 0.57% 2M
|
Health Technology
|
| O: -2.14%
H: 4.18%
C: 2.83%
lung research preclinical therapeutics potential cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.